Message to Shareholders & Investors
To all our stakeholders, we would like to express our deepest gratitude for your continued support and encouragement.
Consolidated Financial Results for FY2022
For FY2022, we posted consolidated net sales of ¥251.5 billion and operating income of ¥18.9 billion. Our operating income ratio was 7.5%.
During the fiscal year, the global economy remained in flux due to accelerated global inflation as well as supply chain disruptions resulting from the conflict between Russia and Ukraine. Our sales increased by 16.5% year-on-year due to strong sales in the Chain segment as well as the overall depreciation of the yen. While our operating income increased by 6.4% year-on-year, our operating income ratio was 7.5%, representing a decrease of 0.8% from the preceding fiscal year. This is attributable to soaring raw material prices and increased labor costs.
Consolidated Earnings Forecast for FY2023
In FY2023, the global economy is expected to remain unpredictable, reflecting the trends toward soaring energy prices, persistent inflation, and widespread adherence to tight monetary policies. We also expect the yen to appreciate, reversing the trend of the previous fiscal year.
In light of these circumstances, we have formulated the following consolidated earnings forecast for FY2023.
Net sales of ¥255.0 billion, an increase of 1.4% year-on-year
Operating income of ¥19.0 billion, an increase of 0.1% year-on-year
In order to achieve the objectives of Mid-Term Management Plan 2025, our Group will reinforce its manufacturing capabilities, continue to strengthen the profitability of existing businesses, and promote the development of new products and businesses. Moreover, we remain committed to expanding our potential for sustainable growth as we evolve into a corporate group that contributes solutions to the challenges facing society. We look forward to the continued support of our shareholders as we pursue these objectives.
Kenji Kose, Chairman and Representative Director
Takatoshi Kimura, President and Representative Director